Publicaciones en colaboración con investigadores/as de University of Oxford (25)

2024

  1. CD137 (4-1BB) and T-Lymphocyte Exhaustion

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 18, pp. 3971-3973

  2. Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming

    Immunological Reviews, Vol. 321, Núm. 1, pp. 143-151

  3. Double-Stranded RNA to Mimic Viral Infection for Cancer Immunotherapy

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 16, pp. 3355-3357

  4. Immunogenicity and Efficacy of Personalized Adjuvant mRNA Cancer Vaccines

    Cancer discovery, Vol. 14, Núm. 11, pp. 2021-2024

  5. Low-Dose Ionizing γ-Radiation Elicits the Extrusion of Neutrophil Extracellular Traps

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 18, pp. 4131-4142

  6. Regional and intratumoral adoptive T-cell therapy

    Immuno-Oncology and Technology, Vol. 24

  7. Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism

    OncoImmunology, Vol. 13, Núm. 1

  8. Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4

  9. Spatially resolved tissue imaging to analyze the tumor immune microenvironment: beyond cell-type densities

    Journal for immunotherapy of cancer, Vol. 12, Núm. 5

  10. The liver as a cytokine factory working on mRNA blueprints for cancer immunotherapy

    Cancer Cell

  11. Tumor slice culture system for ex vivo immunotherapy studies

    Methods in Cell Biology, Vol. 189, pp. 55-69

2023

  1. CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects

    Science advances, Vol. 9, Núm. 33, pp. eadf6692

  2. Druggable Targets in Cytokine Release Syndromes

    Clinical Cancer Research, Vol. 29, Núm. 21, pp. 4320-4322

  3. Facts and Hopes on Neutralization of Protumor Inflammatory Mediators in Cancer Immunotherapy

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 23, pp. 4711-4727

  4. Interleukin-18 in cancer immunology and immunotherapy

    Expert Opinion on Therapeutic Targets, Vol. 27, Núm. 11, pp. 1035-1042

  5. Intraperitoneal administration of a modified vaccinia virus Ankara confers single-chain interleukin-12 expression to the omentum and achieves immune-mediated efficacy against peritoneal carcinomatosis

    Journal for immunotherapy of cancer, Vol. 11, Núm. 11

  6. Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonists

    Molecular Therapy - Nucleic Acids, Vol. 33, pp. 668-682

  7. Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic

    OncoImmunology, Vol. 12, Núm. 1

  8. Single cell spatial analysis reveals inflammatory foci of immature neutrophil and CD8 T cells in COVID-19 lungs

    Nature Communications, Vol. 14, Núm. 1

  9. Spatial transcriptomic characterization of COVID-19 pneumonitis identifies immune circuits related to tissue injury

    JCI Insight, Vol. 8, Núm. 2